Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Can MSC Therapy Help Chronic Lung Inflammation and Scarring?
Transcript
- 0:00SPEAKER_01: Welcome to the Cyrona Cell Podcast.
- 0:02SPEAKER_00: It is great to be here.
- 0:04SPEAKER_01: So today we have a very specific mission for our deep dive.
- 0:08SPEAKER_01: We are looking at a topic that honestly is surrounded by a lot of aggressive marketing and dense science.
- 0:13SPEAKER_00: Yeah, and a lot of desperate hope, too.
- 0:16SPEAKER_01: For sure.
- 0:16SPEAKER_01: When you face a medical diagnosis, you usually expect some clarity.
- 0:20SPEAKER_01: You know, like you break an arm, the doctor points to a jagged white line on an x-ray, and the path forward is obvious.
- 0:26SPEAKER_00: But chronic lung disease is a whole different environment.
- 0:29SPEAKER_01: Aaron Ross Powell It really is.
- 0:31SPEAKER_01: So we are cutting straight through all that noise to ask a very blunt question.
- 0:34SPEAKER_01: What does the actual medical evidence say about whether mesenchymal stem cells can help your chronic lung inflammation and scarring?
- 0:41SPEAKER_00: Aaron Powell And we have to establish a completely grounded reality from the medical literature before we do anything else.
- 0:47SPEAKER_01: Aaron Powell Okay, let's set that baseline.
- 0:49SPEAKER_00: Aaron Powell The central, undeniable message of the current evidence is that no trial shows these cells remove established lung scarring.
- 0:57SPEAKER_00: None.
- 0:58SPEAKER_01: That is a pretty definitive statement.
- 1:00SPEAKER_00: Aaron Powell It is the absolute baseline we operate from.
- 1:03SPEAKER_00: Any clinic or website suggesting they can wipe away existing scar tissue is uh they are just running way ahead of the science.
- 1:10SPEAKER_01: Aaron Powell Knowing that baseline is vital because you will hear a lot of promises out there.
- 1:15SPEAKER_01: And to give you some context on why we are examining this landscape today, um, we should talk about the Cyrona Cell team.
- 1:21SPEAKER_00: Aaron Powell Yep, they operate a regenerative medicine clinic based in Kuala Lumpur.
- 1:25SPEAKER_01: They do.
- 1:25SPEAKER_01: And they serve local patients, but also a significant number of international patients flying in.
- 1:30SPEAKER_01: We are talking notably about people from Australia and the Middle East.
- 1:34SPEAKER_00: Aaron Ross Powell And their specific role is connecting you with partner facilities in Kuala Lumpur, where treating doctors provide the actual care.
- 1:41SPEAKER_01: Aaron Ross Powell But to navigate that process, or honestly, any process involving MSCs, the cells, uh, you really need to understand the biology happening inside your chest.
- 1:50SPEAKER_00: Aaron Ross Powell You have to look at the battlefield of the lung.
- 1:53SPEAKER_01: Aaron Ross Powell Because we hear the terms inflammation and scarring used interchangeably, but they are entirely different biological events.
- 2:00SPEAKER_00: Aaron Powell The American Lung Association, um, in their 2024 guidance, draws a very clear line here.
- 2:06SPEAKER_01: Aaron Powell Okay, how do they define it?
- 2:07SPEAKER_00: Aaron Powell Well, your lungs are exposed to the outside world with every single breath.
- 2:12SPEAKER_00: That means they are constantly taking small hits from dust, pollution, or viruses.
- 2:17SPEAKER_01: Aaron Powell So they are used to a bit of damage.
- 2:20SPEAKER_00: Aaron Powell Yeah.
- 2:21SPEAKER_00: They are actually highly adept at healing from those short-term injuries.
- 2:24SPEAKER_00: The immune system rushes in, clears the debris, and then it leaves.
- 2:29SPEAKER_01: But chronic inflammation is different.
- 2:30SPEAKER_00: Aaron Powell It is.
- 2:31SPEAKER_00: Chronic inflammation occurs when the body's immune system gets stuck in this perpetual attack mode.
- 2:37SPEAKER_00: It constantly bombards the delicate air sacs, causing relentless damage.
- 2:42SPEAKER_01: And over time, that chronic inflammatory state triggers pulmonary fibrosis.
- 2:47SPEAKER_00: Yes.
- 2:47SPEAKER_00: And fibrosis is the permanent scarring of the tissue.
- 2:50SPEAKER_01: Aaron Powell I think of it kind of like a house fire.
- 2:52SPEAKER_01: The inflammation is the active flame.
- 2:54SPEAKER_01: It is eating the drywall, melting the paint, actively destroying the structure.
- 2:58SPEAKER_00: Aaron Powell That is a good way to visualize it.
- 3:00SPEAKER_01: Aaron Powell And the scarring, the fibrosis, is the charred warped wood left behind.
- 3:05SPEAKER_01: You can spray water and put the fire out, but the structural integrity of that wood is just gone.
- 3:10SPEAKER_00: Aaron Powell I would actually push that analogy even further.
- 3:13SPEAKER_01: Oh, how so?
- 3:14SPEAKER_00: The scarred wood in pulmonary fibrosis isn't just dead material sitting there peacefully.
- 3:19SPEAKER_00: It actively prevents the rest of the house from functioning.
- 3:22SPEAKER_01: Aaron Powell Because it's rigid.
- 3:23SPEAKER_00: Aaron Powell Yeah, the scar tissue is stiff and thick.
- 3:26SPEAKER_00: That makes it physically harder for the remaining healthy lung to expand and transfer oxygen.
- 3:31SPEAKER_01: So if a treatment puts out the fire, why do clinics sometimes imply it unburns the wood?
- 3:36SPEAKER_00: Aaron Ross Powell Because the difference matters immensely when anyone makes a treatment claim.
- 3:40SPEAKER_00: And sometimes marketing blurs that line.
- 3:43SPEAKER_00: Putting out the active fire does not unburn the wood.
- 3:46SPEAKER_01: And it certainly doesn't magically rebuild the load-bearing walls.
- 3:49SPEAKER_00: Aaron Powell No, it doesn't.
- 3:51SPEAKER_00: Current standard treatments are designed to smother that active fire and slow the damage down.
- 3:56SPEAKER_00: Understanding this biological difference is your absolute best defense against overblown marketing claims.
- 4:01SPEAKER_01: Okay, so if the charred wood isn't turning back into a pristine stud, what exactly are we looking at in the clinical data?
- 4:08SPEAKER_00: Aaron Powell We need to bypass the theoretical biology and look at the actual human evidence.
- 4:13SPEAKER_01: The medical literature points us to three specific small human trials.
- 4:18SPEAKER_01: Let's analyze the exact parameters of those studies.
- 4:20SPEAKER_00: Aaron Powell We can begin with a 2013 trial.
- 4:22SPEAKER_00: This was a randomized double-blind study involving 62 people diagnosed with chronic obstructive pulmonary disease or COPD.
- 4:31SPEAKER_01: Aaron Powell And they received infusions of the cells, correct?
- 4:34SPEAKER_00: Aaron Ross Powell Yeah, four monthly infusions.
- 4:36SPEAKER_01: Aaron Ross Powell The primary result was that the infusions were well tolerated?
- 4:39SPEAKER_00: Aaron Ross Powell Well what about their actual breathing?
- 4:41SPEAKER_01: Aaron Ross Powell When researchers looked at lung function, how well the patients could actually breathe, there was absolutely no difference between the group receiving the cells and the group receiving a placebo.
- 4:50SPEAKER_00: Aaron Powell Okay.
- 4:50SPEAKER_00: Now I read the post-trial data on that one.
- 4:53SPEAKER_00: The report noted that blood inflammation markers actually dropped for the patients who entered the trial with extremely high levels of inflammation.
- 5:01SPEAKER_01: Aaron Powell They did note that, yes.
- 5:02SPEAKER_00: Aaron Ross Powell So if the goal is putting out the fire, doesn't a drop in inflammation markers prove the treatment works for that specific group?
- 5:09SPEAKER_01: Aaron Ross Powell That is a very common misinterpretation of how clinical data works.
- 5:13SPEAKER_00: Aaron Powell Oh, really?
- 5:14SPEAKER_01: Yeah.
- 5:14SPEAKER_01: The researchers noticed that drop in inflammation markers only after the trial concluded.
- 5:19SPEAKER_01: They went back and sliced the data into specific subgroups of patients.
- 5:23SPEAKER_00: Aaron Ross Powell So they went hunting for a positive result after the fact.
- 5:26SPEAKER_01: Aaron Ross Powell Essentially.
- 5:27SPEAKER_00: Aaron Ross Powell In medical research, finding a trend after the fact is considered a lead.
- 5:32SPEAKER_00: It is a hypothesis generator.
- 5:34SPEAKER_01: Aaron Ross Powell But not definitive proof.
- 5:36SPEAKER_00: Aaron Powell No, you cannot call it definitive proof of benefit because the trial was never designed to measure that specific outcome in that specific subgroup.
- 5:44SPEAKER_01: Aaron Powell It sounds like throwing a dart at a blank wall and then drawing the bullseye around wherever it happens to land.
- 5:49SPEAKER_00: Aaron Ross Powell That is a pretty accurate way to describe post hoc analysis.
- 5:53SPEAKER_00: It is a starting point for future research, but not a conclusion.
- 5:56SPEAKER_01: Aaron Powell Got it.
- 5:57SPEAKER_01: So what happened after that 2013 trial?
- 6:00SPEAKER_00: Aaron Powell Since it didn't show functional lung improvement, researchers had to take a step back.
- 6:05SPEAKER_00: They needed to ask a much more fundamental question regarding a different disease.
- 6:09SPEAKER_00: Aaron Ross Powell Which was Is it even safe to inject these cells into a lung suffering from pulmonary fibrosis?
- 6:16SPEAKER_01: Aaron Ross Powell Ah, so moving from COPD to fibrosis.
- 6:19SPEAKER_00: Aaron Ross Powell Yes.
- 6:20SPEAKER_00: And that question drove a 2017 phase one dose escalation study called the Aether trial.
- 6:25SPEAKER_01: Aaron Ross Powell And that one was tiny, right?
- 6:27SPEAKER_00: Aaron Ross Powell Very small.
- 6:28SPEAKER_00: It involved just nine people.
- 6:29SPEAKER_01: Aaron Ross Powell A phase one trial is purely about safety, though, not whether the treatment actually cures the condition.
- 6:35SPEAKER_00: Aaron Ross Powell That is correct.
- 6:36SPEAKER_00: And the 2017 trial did meet its safety goal.
- 6:39SPEAKER_01: Aaron Ross Powell So the nine patients tolerated the escalating doses without immediate catastrophe.
- 6:44SPEAKER_00: Yes, but the authors explicitly state in their paper that the data is not proof of efficacy.
- 6:50SPEAKER_00: It simply permitted researchers to keep investigating.
- 6:53SPEAKER_01: And that investigation led to the 2020 trial.
- 6:56SPEAKER_00: Aaron Powell It did.
- 6:57SPEAKER_00: This one involved 20 people with fast declining pulmonary fibrosis.
- 7:01SPEAKER_01: Aaron Ross Powell And this was a randomized open label trial, meaning the patients knew they were receiving the cells?
- 7:06SPEAKER_00: Aaron Powell Which is important because it introduces a potential placebo effect into how they feel.
- 7:11SPEAKER_01: Aaron Ross Powell What were the results?
- 7:12SPEAKER_00: Aaron Ross Powell The results showed that patients who received the cells had better walking distances and better gas transfer than the placebo group.
- 7:19SPEAKER_01: Aaron Ross Powell Okay, that sounds positive.
- 7:21SPEAKER_00: Aaron Ross Powell It does.
- 7:22SPEAKER_00: But the computed tomography, the CT scans, showed zero change in their scar scores.
- 7:27SPEAKER_01: Aaron Ross Powell So the visual imaging proved the charred wood was still there.
- 7:31SPEAKER_00: Aaron Ross Powell Yes, the scars remained.
- 7:34SPEAKER_00: And notice how the metrics constantly shift across these studies?
- 7:37SPEAKER_01: Aaron Powell Yeah.
- 7:38SPEAKER_01: The 2013 trial measured lung function tests in COPD.
- 7:41SPEAKER_00: And the 2017 trial measured basic safety.
- 7:44SPEAKER_00: Then the 2020 trial measured a six-minute walk test and CT scans in fast declining fibrosis.
- 7:51SPEAKER_01: Aaron Powell You have three small trials measuring completely different things in completely different patient populations.
- 7:57SPEAKER_00: Exactly.
- 7:58SPEAKER_00: I mean, yes, that is the core issue.
- 8:00SPEAKER_01: Aaron Ross Powell So how is a patient supposed to calculate their personal odds of improvement when the scientists are speaking a different language in every single study?
- 8:08SPEAKER_00: Aaron Powell The blunt truth is that you cannot.
- 8:10SPEAKER_00: Because the trial designs are small and fragmented, researchers have not established a success rate for MSC therapy in lung disease.
- 8:18SPEAKER_01: Aaron Ross Powell So no one should be quoting a percentage chance of getting better.
- 8:21SPEAKER_00: Aaron Powell No.
- 8:22SPEAKER_00: The data does not exist to responsibly tell anyone they have an established success rate.
- 8:26SPEAKER_01: Aaron Powell Here is where I think the entire narrative takes a mind-bending turn.
- 8:31SPEAKER_00: Aaron Powell Okay, what do you mean?
- 8:32SPEAKER_01: Aaron Powell If the CT scans in that 2020 trial show that the physical scars remain exactly the same, how on earth are these patients managing to walk further?
- 8:40SPEAKER_00: Aaron Ross Powell That is the big question.
- 8:42SPEAKER_01: Aaron Powell If the cells aren't turning into healthy new lung tissue, what are they actually doing inside the chest?
- 8:48SPEAKER_00: You've hit on the single biggest misconception regarding regenerative medicine.
- 8:52SPEAKER_01: The idea that they are building blocks.
- 8:54SPEAKER_00: Yeah.
- 8:55SPEAKER_00: When people hear the phrase stem cells, they envision biological replacement parts.
- 9:00SPEAKER_01: Like they assume the infused cells travel through the bloodstream, park themselves in the damaged lung, and physically transform into brand new healthy lung cells.
- 9:08SPEAKER_00: To replace the dead ones, yes.
- 9:09SPEAKER_00: But researchers now propose that they act entirely differently.
- 9:13SPEAKER_01: They don't become lung tissue at all.
- 9:15SPEAKER_00: No, they do not.
- 9:16SPEAKER_00: Instead, they act through something called pericrine signaling.
- 9:19SPEAKER_01: Aaron Ross Powell What does that actually look like?
- 9:23SPEAKER_00: Aaron Powell They release a complex soup of growth factors and anti-inflammatory proteins into the surrounding tissue environment.
- 9:30SPEAKER_01: Wait, so they are just floating around the damaged area releasing proteins.
- 9:35SPEAKER_00: Basically, yes.
- 9:36SPEAKER_01: Think of a chaotic construction zone where workers are haphazardly throwing up walls.
- 9:41SPEAKER_01: The cells aren't arriving with wheelbarrows full of new bricks.
- 9:45SPEAKER_00: Aaron Ross Powell That is a great way to picture it.
- 9:48SPEAKER_01: They are showing up like site managers with megaphones and clipboards blowing whistles to dictate the behavior of the workers already on site.
- 9:55SPEAKER_00: Aaron Ross Powell And the panicked workers in your construction analogy are very specific type of cell called fibroblasts.
- 10:04SPEAKER_00: Yes.
- 10:04SPEAKER_00: Fibroblasts are the cellular machinery responsible for laying down scar collagen.
- 10:09SPEAKER_01: Aaron Ross Powell So in a healthy body they patch a cut and then stop.
- 10:13SPEAKER_00: But in pulmonary fibrosis, they never stop laying collagen.
- 10:16SPEAKER_01: Ah, I see.
- 10:17SPEAKER_00: Aaron Ross Powell The authors of the 2020 trial suggest that the chemical signals released by the MSCs might actually interface with those fibroblasts and dampen their activity.
- 10:27SPEAKER_01: They are essentially telling the construction workers to put the bricks down and stop building the scar.
- 10:32SPEAKER_00: Aaron Powell Yes.
- 10:33SPEAKER_00: And the 2013 COPD trial also pointed to rodent studies, demonstrating that this treatment lowered active lung inflammation.
- 10:42SPEAKER_01: So the cells are attempting to change the local environment, shifting the tissue from a state of chronic alarm to a calmer state.
- 10:48SPEAKER_00: Aaron Powell That is the current working theory, yes.
- 10:50SPEAKER_01: Aaron Powell But if the therapy is entirely dependent on the quality of those site managers and the specific chemical signals they produce, we have to talk about where these cells are coming from.
- 11:01SPEAKER_00: Source dictates behavior, without a doubt.
- 11:03SPEAKER_01: Aaron Powell The 2013 and 2020 trials we just analyzed used cells derived from bone marrow.
- 11:09SPEAKER_01: But bone marrow is just one source, isn't it?
- 11:12SPEAKER_00: Aaron Powell It is.
- 11:13SPEAKER_00: You can derive these cells from bone marrow, fat tissue, placenta, or umbilical cord tissue.
- 11:18SPEAKER_01: Aaron Powell And I assume they don't all act the same way.
- 11:20SPEAKER_00: Aaron Powell Not at all.
- 11:22SPEAKER_00: Each source produces cells with different biological properties.
- 11:25SPEAKER_01: Aaron Ross Powell Because of the variables involved.
- 11:26SPEAKER_00: Aaron Ross Powell Right.
- 11:27SPEAKER_00: Think about things like the age of the donor, the specific tissue harvested, and the amount of time the cells spend culturing and multiplying in a laboratory setting.
- 11:35SPEAKER_01: Aaron Powell So a cell extracted from the bone marrow of a 65-year-old patient will not behave identically to a cell extracted from fresh tissue.
- 11:43SPEAKER_00: Absolutely not.
- 11:44SPEAKER_00: You simply cannot take a clinical result from a trial using bone marrow and magically apply it to a treatment using fat tissue without distinct evidence.
- 11:54SPEAKER_01: Bringing this back to the Cyrona cell context, their program states that they use umbilical cord-derived Wharton's Jelly MSCs, or WJ MSCs.
- 12:02SPEAKER_01: Yes.
- 12:03SPEAKER_01: And just for clarity, Wharton's jelly is the gelatinous substance inside the umbilical cord that protects the blood vessels.
- 12:09SPEAKER_00: That is correct.
- 12:10SPEAKER_01: The clinic states these cells are processed to BSL2, CGMP, and ISO 9001 standards.
- 12:16SPEAKER_00: Which are all manufacturing standards.
- 12:18SPEAKER_01: To a layman, that alphabet soup of acronyms sounds incredibly official, almost like a guarantee of success.
- 12:24SPEAKER_00: Aaron Ross Powell We must firmly separate manufacturing standards from clinical outcomes.
- 12:29SPEAKER_01: Okay, let's break those down.
- 12:30SPEAKER_00: Those acronyms like CGMP, which stands for Current Good Manufacturing Practice, and BSL II, which is Biosafety Level 2, refer entirely to laboratory quality control.
- 12:42SPEAKER_01: Aaron Ross Powell So they indicate that the facility processing the Wharton's jelly is clean and highly regulated.
- 12:48SPEAKER_00: Aaron Powell Yes, and that they follow strict operating procedures to avoid contamination.
- 12:52SPEAKER_01: But they are just the clinic's own manufacturing statements.
- 12:56SPEAKER_00: Aaron Powell They are absolutely not proof of clinical benefit in treating lung disease.
- 13:00SPEAKER_00: They are not regulatory approval endorsing the treatment of pulmonary fibrosis.
- 13:04SPEAKER_01: Aaron Powell They tell you that the product is handled safely in a lab, but they offer zero guarantee of what that product will do once it enters your bloodstream.
- 13:11SPEAKER_00: Aaron Ross Powell Exactly.
- 13:12SPEAKER_00: I mean, yes, that is a crucial distinction to make.
- 13:16SPEAKER_01: If we are introducing systemic biological agents into the bloodstream, we have to look at the dark side of the coin.
- 13:22SPEAKER_00: Aaron Powell The potential downsides.
- 13:24SPEAKER_01: Yeah.
- 13:24SPEAKER_01: What are the specific risks and the unknowns of undergoing this procedure?
- 13:28SPEAKER_00: Aaron Powell Well, the short-term effects reported in the lung trials were generally classified as mild, but they are still significant.
- 13:35SPEAKER_01: Aaron Powell Like what?
- 13:36SPEAKER_00: In the 2020 fibrosis trial, patients receiving the cells experienced transient fever and chills noticeably more often than the placebo group.
- 13:45SPEAKER_01: Aaron Powell That sounds like the body's natural immune reaction to an infusion of a foreign biological substance.
- 13:51SPEAKER_00: It is.
- 13:52SPEAKER_01: But I also noted a much more severe event in that 2020 trial data.
- 13:56SPEAKER_01: One participant actually suffered a stroke.
- 13:59SPEAKER_00: That is a critical data point that definitely requires context.
- 14:02SPEAKER_01: Was it caused by the cells?
- 14:04SPEAKER_00: The trial authors did not definitively link the stroke to the cell infusion itself.
- 14:09SPEAKER_01: But it still happened during the trial.
- 14:11SPEAKER_00: Right.
- 14:12SPEAKER_00: Because it occurred in the treatment group, it must be recorded, evaluated, and discussed as a potential risk factor.
- 14:19SPEAKER_01: Are there any other risks specific to the lungs?
- 14:22SPEAKER_00: Beyond immediate reactions, there is a theoretical concern, highly specific to fibrosis.
- 14:27SPEAKER_01: Okay, what is that?
- 14:28SPEAKER_00: Researchers have noted that in theory, infusing these cells could provoke the fibroblast to act more aggressively.
- 14:35SPEAKER_01: Wait, so the site managers could make the workers build faster?
- 14:39SPEAKER_00: Theoretically, yes, thereby adding to the scarring process rather than stopping it.
- 14:43SPEAKER_01: Did they see that happen?
- 14:45SPEAKER_00: The CT scans in the trial did not show this happening, but the biological mechanism makes it a theoretical risk that has to be acknowledged.
- 14:53SPEAKER_01: And what about the long-term unknowns?
- 14:56SPEAKER_00: The unknowns, frankly, dwarf the knowns.
- 14:59SPEAKER_01: That is not what you want to hear in medicine.
- 15:02SPEAKER_00: No, but it's the truth.
- 15:03SPEAKER_00: The long-term physiological effects of infusing these cells remain entirely unmapped.
- 15:08SPEAKER_01: So we don't know what happens five or ten years down the line.
- 15:11SPEAKER_00: We don't.
- 15:12SPEAKER_00: The medical community also does not know the optimal dose.
- 15:15SPEAKER_01: Or how often you should get it.
- 15:17SPEAKER_00: Right.
- 15:18SPEAKER_00: They do not know the correct schedule, whether a patient needs one infusion or one every month for five years.
- 15:24SPEAKER_01: Aaron Powell That seems like a massive missing piece of the puzzle.
- 15:27SPEAKER_00: Aaron Powell Furthermore, they do not know the ideal patient profile.
- 15:31SPEAKER_00: Does this work better for someone with early stage inflammation or late stage fibrosis?
- 15:36SPEAKER_00: Aaron Powell And the answer is The science simply hasn't answered those questions yet.
- 15:40SPEAKER_01: Aaron Powell Hearing that immense list of unknowns, a very logical conclusion would be to ask why anyone would venture into these murky waters.
- 15:51SPEAKER_01: But with all these open questions, shouldn't someone just stick to their conventional treatments prescribed by a pulmonologist?
- 15:56SPEAKER_00: Aaron Ross Powell Standard Medical C is non-negotiable.
- 15:59SPEAKER_00: It remains the absolute base of any survival strategy.
- 16:02SPEAKER_01: Let's reinforce that.
- 16:04SPEAKER_00: The National Heart, Lung, and Blood Institute is unequivocal in its stance.
- 16:08SPEAKER_00: No cure exists for pulmonary fibrosis.
- 16:10SPEAKER_01: Aaron Powell So the foundation of care is about management.
- 16:13SPEAKER_00: Aaron Powell Yes.
- 16:14SPEAKER_00: It involves antifibrotic medicines, which have robust, proven data demonstrating they slow down lung damage.
- 16:20SPEAKER_01: Aaron Powell And oxygen therapy, I assume.
- 16:22SPEAKER_00: Aaron Powell It definitely involves targeted oxygen therapy to support your failing organs, and it involves rigorous pulmonary rehabilitation to maximize whatever lung function you have left.
- 16:32SPEAKER_01: Aaron Powell So nobody should be throwing their daily inhalers in the trash or canceling their pulmonary rehab appointments because they booked a flight to a regenerative uh clinic.
- 16:41SPEAKER_00: Aaron Powell Never.
- 16:42SPEAKER_00: Any approach involving these cells sits entirely outside standard care.
- 16:46SPEAKER_01: Aaron Powell It's an add-on, not a replacement.
- 16:48SPEAKER_00: Aaron Powell It must be viewed strictly as an experimental adjunct.
- 16:52SPEAKER_00: They do not replace your specialist.
- 16:54SPEAKER_00: They do not replace emergency care protocols.
- 16:56SPEAKER_01: Aaron Powell And they absolutely do not guarantee any medical result.
- 16:59SPEAKER_00: Aaron Powell That is correct.
- 17:00SPEAKER_01: Aaron Powell Let's ground this in a real world scenario.
- 17:02SPEAKER_01: Let's say you live in Malaysia or you are traveling to Kuala Lumpur to explore this option.
- 17:08SPEAKER_00: Okay.
- 17:08SPEAKER_01: How do you navigate this complex, high-risk landscape safely?
- 17:12SPEAKER_01: How do you strip away the glossy brochures and get down to the hard facts?
- 17:16SPEAKER_00: Aaron Ross Powell It requires extreme diligence.
- 17:18SPEAKER_00: And that begins with understanding the local regulatory framework.
- 17:21SPEAKER_01: Aaron Powell Who manages that in Malaysia?
- 17:22SPEAKER_00: Aaron Powell You're dealing with the National Pharmaceutical Regulatory Agency, the NPRA.
- 17:28SPEAKER_01: Aaron Powell Okay, what do they say about all this?
- 17:30SPEAKER_00: Aaron Powell They published the second edition of their cell therapy registration guidance in September 2025.
- 17:35SPEAKER_01: Aaron Ross Powell September 2025?
- 17:38SPEAKER_01: What was the takeaway?
- 17:39SPEAKER_00: Aaron Powell This document is crucial for anyone seeking treatment.
- 17:42SPEAKER_00: It explicitly places cell products that laboratories alter in any way or that act systemically in allogenaic use into the higher-risk class two category.
- 17:52SPEAKER_01: Allogenaic use meaning donor-derived cells from someone else like an umbilical cord.
- 17:57SPEAKER_00: Yes, exactly.
- 17:58SPEAKER_01: A class two high-risk designation means the government recognizes these are not simple vitamin drips.
- 18:05SPEAKER_00: They are complex biological agents acting systemically across your entire body.
- 18:10SPEAKER_01: Picture yourself sitting in a clinic consultation room.
- 18:13SPEAKER_01: We need to build a strict, four-point checklist of things you must demand in writing before you even consider letting a needle near your arm.
- 18:20SPEAKER_00: Demanding documentation changes the entire dynamic of the room.
- 18:24SPEAKER_00: You transition from a passive consumer listening to a sales pitch into an informed patient forcing a conversation about pure evidence.
- 18:40SPEAKER_00: You need to verify if it falls into that higher risk class two.
- 18:44SPEAKER_01: Item two, ask for the published clinical study that covers your exact diagnosis and the specific cell source they are using.
- 18:52SPEAKER_00: This is vital.
- 18:53SPEAKER_00: If you have fast declining pulmonary fibrosis and the clinic is offering umbilical cord cells, you must ask to see the peer-reviewed paper proving that specific combination works.
- 19:13SPEAKER_01: How do they test that?
- 19:14SPEAKER_00: Aaron Ross Powell This usually involves something called a potency assay.
- 19:18SPEAKER_00: You need documentation proving that the specific batch of cells going into your body is actually alive and biologically capable of releasing those signaling factors we discussed.
- 19:27SPEAKER_01: Item four you need the logistical and financial facts in writing.
- 19:32SPEAKER_00: Yes.
- 19:33SPEAKER_00: You need the exact name of the treating doctor at the partner facility.
- 19:36SPEAKER_01: And the risks.
- 19:37SPEAKER_00: You need a written list of potential side effects, a detailed follow-up plan, and the total final cost without hidden fees.
- 19:45SPEAKER_01: If a facility hesitates to provide any of those four items in writing, you have your answer about their clinical standards.
- 19:52SPEAKER_00: It is a massive red flag.
- 19:54SPEAKER_01: We have covered a massive amount of dense medical reality today.
- 19:57SPEAKER_01: Let's recap the grounded truth of this deep dive.
- 19:59SPEAKER_00: The human trials show us that MSCs provide leads.
- 20:03SPEAKER_01: There are hints that they might reduce active inflammation by acting as chemical signaling centers, blowing the whistles to calm down the lung's panicked environment.
- 20:11SPEAKER_00: But the hard, undeniable truth remains.
- 20:13SPEAKER_01: No trial shows they reverse established scarring.
- 20:16SPEAKER_00: The charred wood stays charred.
- 20:18SPEAKER_00: These cells are absolutely not a replacement for your base care, your oxygen therapy, your antifibrotic medicines, or your pulmonary rehab.
- 20:27SPEAKER_01: The most vital step you can take after listening to this analysis is to take this exact information straight to your own lung specialist.
- 20:34SPEAKER_00: You need an open, realistic conversation about your specific pathology, the latest medical evidence, and what goals are actually achievable for your body.
- 20:44SPEAKER_01: If you are actively exploring your options, you can share your medical reports with the Cirona Cell team to see if their treatment pathway might be suitable for your specific case.
- 20:52SPEAKER_00: But remember, the goal of a deep dive is to equip you with the precise questions you need to ask, not to provide you with medical advice.
- 21:00SPEAKER_01: The scientific evidence provides the map, but your personal specialist remains your guide.
- 21:04SPEAKER_00: Always.
- 21:05SPEAKER_01: I want to leave you with a final thought to mull over.
- 21:08SPEAKER_01: For centuries, we have looked at medicine as a highly mechanical process.
- 21:12SPEAKER_01: We cut out the bad parts and we transplant in new parts to fix a broken machine.
- 21:16SPEAKER_00: It is a very structural way of thinking.
- 21:19SPEAKER_01: But how fascinating is it that the future of medicine might look completely different?
- 21:24SPEAKER_01: The frontier we are approaching might not rely on transplanting new parts at all.
- 21:28SPEAKER_00: A completely different approach.
- 21:31SPEAKER_01: Instead, it might rely entirely on delivering a new set of chemical instructions to help the body manage its own chronic alarms.
- 21:38SPEAKER_01: The fire might have already done its structural damage, but learning how to finally turn off the body's alarm system is a frontier worth watching.
- 21:47SPEAKER_01: Thanks for joining us.